Online citations, reference lists, and bibliographies.
← Back to Search

Therapie Des Malignen Pleuramesothelioms

H. Huwer, A. Bücker
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
ZusammenfassungDie chirurgischen Maßnahmen zur Behandlung des malignen Pleuramesothelioms sind Pleurektomie mit Dekortikation und extrapleurale Pneumonektomie. Die extrapleurale Pneumonektomie, historisch mit einer hohen Letalität verbunden, wird heutzutage in erfahrenen Zentren mit der gleichen Letalität wie eine Standardpneumonektomie durchgeführt. Dieser Artikel beschreibt beide Operationen und diskutiert postoperative Komplikationen, klinische Resultate und Rezidivmuster nach den entsprechenden operativen Maßnahmen. Zusätzlich werden das Stagingsystem der International Mesothelioma Interest Group (IMIG) und andere prognostische Parameter dargestellt; pathologische und epidemiologische Besonderheiten des malignen Pleuramesothelioms werden erwähnt.AbstractThe principal surgical options for the treatment of malignant pleural mesothelioma are pleurectomy and decortication or extrapleural pneumonectomy. Although previously associated with high lethality rates, extrapleural pneumonectomy can be performed today at experienced centers with the same risk of lethality as standard pneumonectomy. This article provides a description of both surgical procedures and discusses complications, clinical results and recurrence patterns. In addition, the staging system proposed by the International Mesothelioma Interest Group (IMIG) and other prognostic parameters are detailed. Mention is also made of the pathological and epidemiological characteristics of malignant plural mesothelioma.
This paper references
Problems in mesothelioma diagnosis
Bruce Addis (2009)
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
Malignant pleural mesothelioma.
A. Tsao (2009)
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Surgery and multimodality treatment for malignant pleural mesothelioma
Walter Weder (2009)
Indications for pleurectomy in malignant effusion
N. Martini (1975)
201 Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM)
P. Zucali (2006)
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
Aktueller Stand und neue Möglichkeiten der modernen Strahlentherapie
M. Muenter (2005)
Möglichkeiten und Ergebnisse der chirurgischen Behandlung des malignen Pleuramesothelioms
H. Wörn (1974)
Phase II study of vinflunine in malignant pleural mesothelioma.
D. Talbot (2007)
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
O. Soysal (1997)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Post-Pleuropneumonectomy Herniation of Liver Mimicking Major Pulmonary Embolism
H. Huwer (2006)
Extrapleural Pneumonectomy and Pleurectomy in Pulmonary Tuberculosis *
I. A. Sarot (1949)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
M. Davalle (1986)
H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study.
U. Suleiman (2000)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
[Pleuro-pneumo-phreno-pericardiectomy with pericardial and diaphragmatic plasty].
L. Politi (2001)
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
S. Grondin (1999)
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
J. Sørensen (2008)
Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma
M. Di Salvo (2008)
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice
C. Lee (2007)
Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM).
M. Reck (2009)
Modern thirty-day operative mortality for surgical resections in lung cancer.
R. Ginsberg (1983)
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).
J. Dowell (2009)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2006)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Localized Malignant Mesothelioma: A Clinicopathologic and Flow Cytometric Study
T. Crotty (1994)
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
K. Allen (1994)
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
A. Nowak (2008)
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
S. Mikulski (2002)
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.
M. Chang (2004)
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar